Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia

Familial hypercholesterolemia (FH) is a common inherited disorder of low density lipoprotein-cholesterol (LDL-C) metabolism. It is associated with higher risk of premature coronary heart disease. Around 60% of patients with a clinical diagnosis of FH do not have a detectable mutation in the genes ca...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2017-08, Vol.263, p.405-411
Main Authors: Sharifi, Mahtab, Higginson, Elizabeth, Bos, Sven, Gallivan, Angela, Harvey, Darren, Li, Ka Wah, Abeysekera, Amali, Haddon, Angela, Ashby, Helen, Shipman, Kate E., Cooper, Jackie A., Futema, Marta, Roeters van Lennep, Jeanine E., Sijbrands, Eric J.G., Labib, Mourad, Nair, Devaki, Humphries, Steve E.
Format: Article
Language:English
Subjects:
Adult
Aged
Asymptomatic Diseases
Biomarkers - blood
Carotid Artery Diseases - blood
Carotid Artery Diseases - diagnostic imaging
Carotid Artery Diseases - etiology
Carotid Intima-Media Thickness
Cholesterol, LDL - blood
Computed Tomography Angiography
Coronary Angiography - methods
Coronary artery calcification
Coronary Artery Disease - blood
Coronary Artery Disease - diagnostic imaging
Coronary Artery Disease - etiology
DNA Mutational Analysis
England
Familial hypercholesterolemia
Female
Genetic Predisposition to Disease
Humans
Hyperlipoproteinemia Type II - blood
Hyperlipoproteinemia Type II - complications
Hyperlipoproteinemia Type II - drug therapy
Hyperlipoproteinemia Type II - genetics
Male
Middle Aged
Multifactorial Inheritance
Mutation
Netherlands
Phenotype
Polygenic hypercholesterolemia
Polymorphism, Single Nucleotide
Preclinical atherosclerosis
Risk Factors
Severity of Illness Index
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Familial hypercholesterolemia (FH) is a common inherited disorder of low density lipoprotein-cholesterol (LDL-C) metabolism. It is associated with higher risk of premature coronary heart disease. Around 60% of patients with a clinical diagnosis of FH do not have a detectable mutation in the genes causing FH and are most likely to have a polygenic cause for their raised LDL-C. We assessed the degree of preclinical atherosclerosis in treated patients with monogenic FH versus polygenic hypercholesterolemia. FH mutation testing and genotypes of six LDL-C-associated single nucleotide polymorphisms (SNPs) were determined using routine methods. Those with a detected mutation (monogenic) and mutation-negative patients with LDL-C SNP score in the top two quartiles (polygenic) were recruited. Carotid intima media thickness (IMT) was measured by B-mode ultrasound and the coronary artery calcium (CAC) score was performed in three lipid clinics in the UK and the Netherlands. 86 patients (56 monogenic FH, 30 polygenic) with carotid IMT measurement, and 166 patients (124 monogenic, 42 polygenic) with CAC score measurement were examined. After adjustment for age and gender, the mean of all the carotid IMT measurements and CAC scores were significantly greater in the monogenic than the polygenic patients [carotid IMT mean (95% CI): 0.74 mm (0.7–0.79) vs. 0.66 mm (0.61–0.72), p = 0.038 and CAC score mean (95%): 24.5 (14.4–41.8) vs. 2.65 (0.94–7.44), p = 0.0004]. In patients with a diagnosis of FH, those with a monogenic cause have a higher severity of carotid and coronary preclinical atherosclerosis than those with a polygenic aetiology. •Patients with clinical FH but no detectable mutation are likely to have a polygenic cause for their raised LDL-C.•Preclinical atherosclerosis was measured in both groups, matched for lipid levels.•Carotid Intima Media Thickness was greater in monogenic vs polygenic patients.•Coronary artery calcification score was greater in monogenic vs polygenic patients.•Monogenic FH patients have greater preclinical atherosclerosis than those with a polygenic aetiology.
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2017.05.015